Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Cited In for PubMed (Select 8910276)

1.

Identifying cryptic population structure in multigenerational pedigrees in a Mexican American sample.

Culverhouse RC, Hinrichs AL, Suarez BK.

BMC Proc. 2014 Jun 17;8(Suppl 1):S4. doi: 10.1186/1753-6561-8-S1-S4. eCollection 2014.

2.

Molecular pathways in prostate cancer.

Mazaris E, Tsiotras A.

Nephrourol Mon. 2013 Jul 1;5(3):792-800. doi: 10.5812/numonthly.9430. Epub 2013 Jun 8. Review.

3.

Inflammatory genetic markers of prostate cancer risk.

Tindall EA, Hayes VM, Petersen DC.

Cancers (Basel). 2010 Jun 8;2(2):1198-220. doi: 10.3390/cancers2021198.

4.

Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population.

San Francisco IF, Rojas PA, Torres-Estay V, Smalley S, Cerda-Infante J, Montecinos VP, Hurtado C, Godoy AS.

J Cell Mol Med. 2014 Jan;18(1):125-33. doi: 10.1111/jcmm.12171. Epub 2013 Nov 14.

5.

Prostate cancer risk-associated genetic markers and their potential clinical utility.

Xu J, Sun J, Zheng SL.

Asian J Androl. 2013 May;15(3):314-22. doi: 10.1038/aja.2013.42. Epub 2013 Apr 8.

6.

Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.

Mi Y, Yu Q, Min Z, Xu B, Zhang L, Zhang W, Feng N, Hua L.

J Biomed Res. 2010 Sep;24(5):365-73. doi: 10.1016/S1674-8301(10)60049-8.

7.

Familial prostate cancer: the damage done and lessons learnt.

Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.

Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.

8.

Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.

Zuhlke KA, Johnson AM, Okoth LA, Stoffel EM, Robbins CM, Tembe WA, Salinas CA, Zheng SL, Xu J, Carpten JD, Lange EM, Isaacs WB, Cooney KA.

Fam Cancer. 2012 Dec;11(4):595-600. doi: 10.1007/s10689-012-9555-1.

9.

Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families.

Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Bochum S, Hoegel J, Grönberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB; International Consortium for Prostate Cancer Genetics.

BMC Med Genet. 2012 Jun 19;13:46. doi: 10.1186/1471-2350-13-46.

10.

XMRV Discovery and Prostate Cancer-Related Research.

Kang DE, Lee MC, Das Gupta J, Klein EA, Silverman RH.

Adv Virol. 2011;2011:432837. doi: 10.1155/2011/432837. Epub 2011 Jun 21.

11.

The genetics of cancer risk.

Pomerantz MM, Freedman ML.

Cancer J. 2011 Nov-Dec;17(6):416-22. doi: 10.1097/PPO.0b013e31823e5387. Review.

12.

Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Theodore S, Sharp S, Zhou J, Turner T, Li H, Miki J, Ji Y, Patel V, Yates C, Rhim JS.

Int J Oncol. 2010 Dec;37(6):1477-82.

13.

Androgen receptor signaling and mutations in prostate cancer.

Koochekpour S.

Asian J Androl. 2010 Sep;12(5):639-57. doi: 10.1038/aja.2010.89. Epub 2010 Aug 16. Review.

14.

Genetic variation in RNASEL associated with prostate cancer risk and progression.

Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA.

Carcinogenesis. 2010 Sep;31(9):1597-603. doi: 10.1093/carcin/bgq132. Epub 2010 Jun 24.

15.

Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.

Agalliu I, Leanza SM, Smith L, Trent JM, Carpten JD, Bailey-Wilson JE, Burk RD.

Prostate. 2010 Nov 1;70(15):1716-27. doi: 10.1002/pros.21207.

16.

Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.

Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Farnham JM, Cannon-Albright LA, Camp NJ; International Consortium for Prostate Cancer Genetics.

Prostate. 2010 May 15;70(7):735-44. doi: 10.1002/pros.21106.

17.

The clinical genetics of prostate cancer.

Kommu S, Edwards S, Eeles R.

Hered Cancer Clin Pract. 2004 Jul 15;2(3):111-21. doi: 10.1186/1897-4287-2-3-111.

18.

Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Hu SY, Liu T, Liu ZZ, Ledet E, Velasco-Gonzalez C, Mandal DM, Koochekpour S.

Asian J Androl. 2010 May;12(3):336-43. doi: 10.1038/aja.2010.5. Epub 2010 Feb 22.

19.

Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd LC.

Prostate. 2010 Mar 1;70(4):341-52. doi: 10.1002/pros.21067.

20.

Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.

Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, Miller K, Kurth R, Bannert N.

Retrovirology. 2009 Oct 16;6:92. doi: 10.1186/1742-4690-6-92.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk